Other Publication Details
Mandatory Fields
Reviews
Swan, D;Gurney, M;Krawczyk, J;Ryan, AE;O'Dwyer, M
2020
April
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Published
1
Optional Fields
LOW-DOSE CYCLOPHOSPHAMIDE REGULATORY T-CELLS SUPPRESSOR-CELLS IMMUNE-RESPONSE DENDRITIC CELLS B-CELL ALDEHYDE DEHYDROGENASE MURINE MELANOMA BONE-MARROW ARGINASE-I
The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.
PHILADELPHIA
LIPPINCOTT WILLIAMS & WILKINS
2572-9241
10.1097/HS9.0000000000000350
Grant Details
Publication Themes